Rakuten Med
San Diego, US · Founded 2010 · 1 known investors
Find your way into Rakuten Med
Sign up to see every warm intro you have to Rakuten Med
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Rakuten Med team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Rakuten Medical is a global biotechnology company that develops and commercializes precision cell-targeting photoimmunotherapy treatments for cancer using its proprietary Alluminox platform. The company focuses on creating innovative cancer treatment options and bringing them to patients worldwide.
Founders & leadership
AB

Abhijit BhatiaChief Operating Officer (COO)Abhijit Bhatia is an executive officer at Rakuten Medical, a biotechnology company developing precision cell-targeting photoimmunotherapy cancer treatments using its Alluminox platform. He brings expertise in business strategy, corporate partnerships, deal negotiation, and commercialization within the life sciences sector.
TP
Tiffany PiecewiczGeneral CounselTiffany Piecewicz is an attorney with 15+ years of experience in corporate governance, intellectual property litigation, employment law, and contract disputes across multinational organizations. She has managed strategic matters for cases valued up to $14B and has worked on international corporate compliance projects in Europe.
SS
Suzane SanChief People OfficerSuzane San is an Executive Officer at Rakuten Medical with over 15 years of experience in people operations and organizational development within the biotechnology sector. Her background includes designing and implementing HR programs, advising on personnel matters, and supporting organizational growth across biotech companies.
MM
Minami MaedaExecutive
LC

Louise ChangChief Strategy OfficerLouise Chang is Chief Strategy Officer at Rakuten Medical, where she oversees corporate strategy, investor relations, and clinical program governance. She has over a decade of healthcare industry experience, including prior roles at Johnson & Johnson China and E-SUN Commercial Bank.
AT
Amy ThorneExecutive
HD
Hassan DanesiExecutive
Investors · 1
Reported raises · per SEC filings
Form D private placements$908.3M disclosed across 17 rounds · 2014–2026
▶$9MraisedOct 2026 · 14 investors · BiotechnologyRule 506(b)
▶$9MraisedOct 2026 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Maeda MinamiExecutive Officer
- David ChaoDirector
- Miguel Garcia-GuzmanDirector
- Hiroshi MikitaniDirector
- Hiroshi MoriDirector
- Ken TakeshitaDirector
- Christophe WeberDirector
- Nitin NohriaDirector
- Eiichi KagaDirector
- Mazen DarwazehDirector
- Tiffany PiecewiczExecutive Officer
- Abhijit BhatiaExecutive Officer
- Toshiaki SuzukiExecutive Officer
- Suzane SanExecutive Officer
- Hiroyuki KodamaExecutive Officer
- Louise ChangExecutive Officer
- Amy ThorneExecutive Officer
- Anthony ManibusanExecutive Officer
- Hassan DanesiExecutive Officer
- Offering amount
- $9M
- Amount sold
- $9M
- First sale
- Aug 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$111.5MraisedApr 2026 · 26 investors · BiotechnologyRule 506(b)
▶$111.5MraisedApr 2026 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Hiroshi MoriDirector
- Hiroyuki KodamaExecutive Officer
- Hiroshi MikitaniExecutive Officer, Director
- Suzane SanExecutive Officer
- David ChaoDirector
- Toshiaki SuzukiExecutive Officer
- Carlos GarciaExecutive Officer
- Maeda MinamiExecutive Officer
- Abhijit BhatiaExecutive Officer
- Kentaro HyakunoDirector
- Nitin NohriaDirector
- Mazen DarwazahDirector
- Eiichi KagaDirector
- Miguel Garcia-GuzmanDirector
- Tiffany PiecewiczExecutive Officer
- Offering amount
- $116.7M
- Amount sold
- $111.5M
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.9MraisedMay 2025 · 14 investors · BiotechnologyRule 506(b)
▶$1.9MraisedMay 2025 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Abhijit BhatiaExecutive Officer
- Nitin NohriaDirector
- David ChaoDirector
- Tiffany PiecewiczExecutive Officer
- Mazen DarwazahDirector
- Suzane SanExecutive Officer
- Hiroshi MikitaniExecutive Officer, Director
- Hiroshi MoriDirector
- Miguel Garcia-GuzmanDirector
- Eiichi KagaDirector
- Minami MaedaExecutive Officer
- Toshiaki SuzukiExecutive Officer
- Carlos GarciaExecutive Officer
- Kentaro HyakunoDirector
- Offering amount
- $1.9M
- Amount sold
- $1.9M
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.2MraisedMar 2024 · 15 investors · BiotechnologyRule 506(b)
▶$4.2MraisedMar 2024 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David ChaoDirector
- Carlos GarciaExecutive Officer
- Mazen DarwazahDirector
- Suzane SanExecutive Officer
- Hiroshi MoriDirector
- Hiroshi MikitaniExecutive Officer, Director
- Kentaro HyakunoDirector
- Hiroshi TakasawaDirector
- Nitin NohriaDirector
- Miguel Garcia-GuzmanDirector
- Takashi ToraishiExecutive Officer, Director
- Abhijit BhatiaExecutive Officer
- Agatha MartindaleExecutive Officer
- Minami MaedaExecutive Officer
- Tiffany PiecewiczExecutive Officer
- Toshiaki SuzukiExecutive Officer
- Offering amount
- $4.2M
- Amount sold
- $4.2M
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.2MraisedOct 2023 · 20 investors · BiotechnologyRule 506(b)
▶$2.2MraisedOct 2023 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kentaro HyakunoDirector
- Mazen DarwazehDirector
- Hiroshi MoriDirector
- Nitin NohriaDirector
- David ChaoDirector
- Toshiaki SuzukiExecutive Officer
- Takashi ToraishiExecutive Officer, Director
- Abhijit BhatiaExecutive Officer
- Tiffany PiecewiczExecutive Officer
- Hiroshi TakasawaDirector
- Hiroshi MikitaniExecutive Officer, Director
- Miguel Garcia-GuzmanDirector
- Carlos GarciaExecutive Officer
- Offering amount
- $2.2M
- Amount sold
- $2.2M
- First sale
- Jun 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$104.8MraisedSep 2023 · 15 investors · BiotechnologyRule 506(b)
▶$104.8MraisedSep 2023 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tiffany PiecewiczExecutive Officer
- Miguel Garcia-GuzmanDirector
- Nitin NohriaDirector
- David ChaoDirector
- Carlos GarciaExecutive Officer
- Mazen DarwazehDirector
- Takashi ToraishiExecutive Officer, Director
- Kentaro HyakunoDirector
- Hiroshi MikitaniExecutive Officer, Director
- Abhijit BhatiaExecutive Officer
- Hiroshi MoriDirector
- Hiroshi TakasawaDirector
- Offering amount
- $123.7M
- Amount sold
- $104.8M
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$70MraisedDec 2022 · 4 investors · BiotechnologyRule 506(b)
▶$70MraisedDec 2022 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Miguel Garcia-GuzmanDirector
- Carlos GarciaExecutive Officer
- Tiffany PiecewiczExecutive Officer
- Hiroshi MoriDirector
- David ChaoDirector
- Kentaro HyakunoDirector
- Abhijit BhatiaExecutive Officer
- Takashi ToraishiExecutive Officer, Director
- Nitin NohriaDirector
- Hiroshi MikitaniExecutive Officer, Director
- Hiroshi TakasawaDirector
- Offering amount
- $90M
- Amount sold
- $70M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$166MraisedJul 2021 · 10 investors · BiotechnologyRule 506(b)
▶$166MraisedJul 2021 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Miguel Garcia-GuzmanExecutive Officer, Director
- David ChaoDirector
- Takashi ToraishiExecutive Officer, Director
- Kentaro HyakunoDirector
- Ann McGuireExecutive Officer
- Hiroshi MoriDirector
- Carlos GarciaExecutive Officer
- Hiroshi TakasawaDirector
- Nitin NohriaDirector
- Hiroshi MikitaniExecutive Officer, Director
- Offering amount
- $291M
- Amount sold
- $166M
- Sales commissions
- $3M
- Placement agents
- TAP Securities LLC, Momentum Capital Markets, LLC
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
MD Anderson Cancer CenterUT MD Anderson is a cancer research and treatment center that provides patient care, conducts research, and offers education in cancer prevention and treatment. It is part of the University of Texas System and operates as a nonprofit medical institution.
GlobaldataGlobalData provides an AI-powered intelligence platform that delivers research, market analysis, and predictive insights to enterprises across industries. The platform combines proprietary data, in-house subject matter experts, and AI tools to support critical business decisions.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Kura OncologyKura Oncology is a company in the oncology/medtech sector that provides grant support for independent medical education programs designed to enhance healthcare professionals' ability to diagnose and treat patients in Kura Oncology's therapeutic areas of interest.
Companies working in the same space as Rakuten Med.
Frequently asked questions
- What does Rakuten Med do?
- Rakuten Medical is a global biotechnology company that develops and commercializes precision cell-targeting photoimmunotherapy treatments for cancer using its proprietary Alluminox platform. The company focuses on creating innovative cancer treatment options and bringing them to patients worldwide.
- Who are Rakuten Med's investors?
- Rakuten Med's investors include Taiwania Capital.
- How much funding has Rakuten Med raised?
- Rakuten Med has disclosed $908.3M raised across 17 rounds.
- Where is Rakuten Med headquartered?
- Rakuten Med is headquartered in San Diego, US.







